Supplementary Methods and Figures S1-S3
3503 Background: Despite adjuvant chemotherapy (ACT) a proportion of patients (pts) with stage III colon cancer (CC) will recur. Most at risk are those with detectable ctDNA, whereas those with undetectable ctDNA have a reduced recurrence risk. The DYNAMIC-III study explored the impact of ACT de-escalation or escalation as informed by post-surgery ctDNA results. Here, we report the primary analysis on the impact of treatment escalation in ctDNA-positive pts. Outcome data for treatment de-escalation in ctDNA-negative pts is immature. Methods: DYNAMIC-III is a multi-center, randomized, phase II/III trial. Eligible pts had resected stage III CC and were fit for ACT. Pts were randomly assigned 1:1 to ctDNA-informed or standard of care (SOC) management. Clinicians nominated the selected SOC ACT regimen prior to randomization. For ctDNA-informed management, a ctDNA-positive result at 5-6 weeks after surgery with a tumor-informed assay prompted an escalation ACT strategy (from single agent fluoropyrimidine [FP] to oxaliplatin-based doublet, from 3 months doublet to 6 months doublet or FOLFOXIRI [clinician choice], or from 6 months doublet to FOLFOXIRI). The primary efficacy endpoint for the ctDNA-positive cohort was 2-year RFS. The target sample size of 250 provided 80% power with 90% confidence to confirm superiority of ctDNA-informed treatment escalation compared to SOC with a HR of 0.746. Results: Of 961 eligible pts randomized between Oct 2017 and Apr 2023, 259 (27%) were ctDNA-positive. Of these, 113 (44%) had clinical low risk disease (non-N2 + non-T4). Median follow-up was 42.2 months (range 0.78 – 63.0). 115 (89%) of 129 ctDNA-informed pts received ACT escalation, with 65 (56%) receiving FOLFOXIRI. Of 130 SOC pts, 14 (11%) and 112 (86%) received single agent FP and oxaliplatin doublet, respectively. 2-year RFS for ctDNA-informed treatment escalation was 52% (90% CI: 44 - 59%) vs 61% (90% CI: 54 - 68%) for SOC (HR 1.11, 90% CI: 0.83 - 1.48; P = 0.6). The 3-year RFS for ctDNA-positive pts receiving FOLFOXIRI and FOLFOX/CAPOX was similar (47% vs 51%, HR 1.09, 90% CI 0.78 to 1.53; P = 0.7). In a pre-specified correlative analysis of all ctDNA positive pts, recurrence risk increased with ctDNA burden, with 3-year RFS of 78%, 63%, 36% and 22% for tumor-derived mutant molecules/mL quartiles < 0.06, 0.06 – 0.17, 0.18 – 1.31, and > 1.31, respectively (P < 0.01). Treatment-related hospitalisation was similar for escalated and SOC pts (OR 1.21, P = 0.58). Analysis of post-ACT ctDNA is underway. Conclusions: In this first randomised study of ctDNA-informed management in stage III CC, we confirm the prognostic significance of detectable ctDNA, with the novel finding of recurrence risk increasing markedly with ctDNA burden. Treatment escalation, including to FOLFOXIRI, did not improve RFS. Future studies in ctDNA positive pts should explore other escalation strategies. Clinical trial information: ACTRN12617001566325 .
The prevalence of pathogenic or likely pathogenic variants (PVs) in breast cancer susceptibility genes in the US population—regardless of family history risk factors—remains largely unknown because population-based genetic screening is not routinely performed. To identify the prevalence of PVs in a large cohort of women offered criteria-independent genetic testing and to evaluate the relationship of test positivity to family history and other patient characteristics. The Women Informed to Screen Depending on Measures of Risk (WISDOM) randomized clinical trial enrolled women without breast cancer aged 40 to 74 years between August 2016 and February 2023 in a pragmatic randomized screening trial comparing annual screening mammography with personalized risk-based screening. Data were analyzed from August 2023 to November 2025. All women in the personalized screening arm were offered germline testing for 9 breast cancer susceptibility genes: BRCA1 , BRCA2 , ATM , CHEK2 , PALB2 , CDH1 , PTEN , STK11 , and TP53 . The prevalence of PVs in the trial and the distribution of self-reported demographic and family history data in this subpopulation of carriers. Among 23 098 women who completed germline genetic testing (mean [SD] age, 54.3 [9.6] years), 714 (3.1%) carried a PV. Excluding 109 who were previously aware of their PV, the detection rate was 2.6%. PVs were most common in CHEK2 (337 [1.5%]) and ATM (101 [0.4%]) but less common in higher-penetrance genes ( BRCA1 , 33 [0.1%]; BRCA2 , 82 [0.4%]; PALB2 , 44 [0.2%]). PVs in the CDH1 , PTEN , STK11 , and TP53 genes were rare (less than 0.1%). Notably, 180 of 605 women with PVs (29.8%) did not report a first-degree or second-degree female relative with breast or ovarian cancer, male relative with breast cancer, or Jewish ancestry. In this secondary analysis of the WISDOM trial, criteria-independent genetic testing in a pragmatic trial identified a substantial number of women with clinically actionable results, many of whom would not have qualified for genetic testing under current guidelines. These findings support broader access to genetic testing as part of personalized breast cancer risk assessment. ClinicalTrials.gov Identifier: NCT02620852
Mono-allelic germline pathogenic variants (GPVs) in MMR genes (MLH1, MSH2, PMS2, and MSH6) predispose individuals to hereditary non-polyposis colorectal cancer (HNPCC), better known now as Lynch syndrome (LS). Bi-allelic GPVs in MMR genes lead to a severe phenotype, constitutional MMR deficiency (CMMRD), that is characterized by early onset of leukemia/lymphoma, colorectal/gastrointestinal tumors, brain tumors, and sarcomas. MMR deficient mouse models have provided many mechanistic and translational insights. Pms2-null (Pms2ko/ko) mice were found to be viable but showed an increase in microsatellite instability and developed lymphomas and sarcomas. One of the most frequently occurring human mutations in PMS2 is a founder mutation NM_000535.5:c.2002A>G (p.I668V), observed in the Canadian Inuit population (1 in 16 Inuits are carriers). This mutation acts as a de novo splice site that creates a 5 bp deletion resulting in a truncated protein (p.I668*). A mouse model with an equivalent germline mutation (Pms2c.1993A>G) results in a splicing defect like that observed in humans and exhibits a significant increase in microsatellite instability and intestinal adenomas on an Apc mutant (Apctm1Rak ) background. We are now further characterizing this model for intestinal tumor initiation and progression using time course experiments and comparing tumor development by histopathological examination with the Pms2ko/ko model. Moreover, we are also examining this model to identify neoantigens, that may lead to development of a new vaccine for PMS2 mutation carriers.This mouse model can be a valuable tool to test the efficacy of new strategies for cancer prevention in PMS2 mutation carriers. We have developed a luciferase based splicing reporter assay in HEK293 cells that can be used to screen splicing modulators to suppress aberrant splicing of this splice site mutation. The efficacy of these modulators to suppress aberrant splicing in the small intestine of mice can be further tested using this mouse model. Kajal Biswas, Yurong Song, Vaishnavi Peddibhotla, Brandon Somerville, Mary Albaugh, Dillon Dierman, Rameesha Mustafa, Altaf Mohammed, Shyam K. Sharan, Robert H. Shoemaker. A novel PMS2 mutant Lynch syndrome mouse model for cancer prevention studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6337.